Muscle targeting complexes and formulations for treating myotonic dystrophy

US11931421B2 · kind B2 · utility

Assignee

• Dyne Therapeutics, Inc. · US

Inventors

• Scott A. Hilderbrand · Swampscott, US
• Timothy Weeden · Waltham, US
• John Najim · Waltham, US
• Stefano Zanotti · Waltham, US
• Romesh R. Subramanian · Framingham, US
• Mohammed T. Qatanani · Waltham, US
• Cody A. Desjardins · Waltham, US
• Kim Tang · Belmont, US
• Brendan Quinn · Boston, US

Key dates

• Filing date: Apr 19, 2023
• Grant date: Mar 19, 2024
• Expiry date: Apr 19, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).